BRCA2 and neoplasm: Since the induction of mCXCL10 could be part of the beneficial effect of olaparib in the Brca2(−/−) model, and as we observed that Brca2 wild-type ID8-Trp53(−/−) cells could be stimulated by olaparib to induce this chemokine as well, we wondered whether olaparib efficacy could be improved in Brca2 wild-type tumours by optimising olaparib dosage and adding a DPP4 inhibitor.